Portal de Periódicos da CAPES

Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

2017; Elsevier BV; Volume: 49; Issue: 4 Linguagem: Inglês

10.1016/j.dld.2017.01.141

1878-3562

Livia Biancone, Vito Annese, Sandro Ardizzone, Alessandro Armuzzi, Emma Calabrese, Flavio Caprioli, Fabiana Castiglione, Michele Comberlato, Mario Cottone, Silvio Danese, Marco Daperno, R. D’Incà, Giuseppe Frieri, Walter Fries, Paolo Gionchetti, Anna Kohn, Giovanni Latella, Mónica Milla, Ambrogio Orlando, Claudio Papi, C. Petruzziello, Gabriele Riegler, Fernando Rizzello, Simone Saibeni, Maria Lia Scribano, Maurizio Vecchi, Piero Vernia, Gianmichele Meucci, Annalisa Aratari, Fabrizio Bossa, Maria Cappello, A. Cassinotti, Alberto Chiriatti, Gionata Fiorino, Vincenzo Formica, Luisa Guidi, Alessandra Losco, Filippo Mocciaro, S. Onali, Luca Pastorelli, Roberta Pica, Mariabeatrice Principi, Sara Renna, Chiara Ricci, Antonio Rispo, Francesca Rogai, Loredana Sarmati, Franco Scaldaferri, Luisa Spina, R. Tambasco, Anna Testa, Angelo Viscido,

Pregnancy and Medication Impact

Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn's disease and ulcerative colitis is unknown, due to the current knowledge regarding their pathogenesis, effective treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs. These observations prompted the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) to establish Italian guidelines on the safety of currently available treatments for Crohn's disease and ulcerative colitis. These guidelines discuss the use of aminosalicylates, systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNFα antagonists, vedolizumab, and combination therapies. These guidelines are based on current knowledge derived from evidence-based medicine coupled with clinical experience of a national working group.